{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T01:45:40Z","timestamp":1788659140763,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T00:00:00Z","timestamp":1498435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00280-017-3371-0","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T02:20:12Z","timestamp":1498443612000},"page":"333-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer"],"prefix":"10.1007","volume":"80","author":[{"given":"Kotoe","family":"Takayoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Uenomachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Mitsugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinatsu","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Inadomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ariyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9428-6772","authenticated-orcid":false,"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"3371_CR1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrclinonc.2013.132","volume":"10","author":"K Radhav","year":"2013","unstructured":"Radhav K, Overman MJ (2013) Small bowel adenocarcinoma-existing evidence and evolving paradigm. Nat Rev Clin Oncol 10:534\u2013544","journal-title":"Nat Rev Clin Oncol"},{"key":"3371_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","volume":"249","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS (2009) Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 249:63\u201371. doi:\n                        10.1097\/SLA.0b013e31818e4641","journal-title":"Ann Surg"},{"key":"3371_CR3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.20404","volume":"101","author":"BS Dabaja","year":"2004","unstructured":"Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J (2004) Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101:518\u2013526","journal-title":"Cancer"},{"key":"3371_CR4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.137.5.564","volume":"137","author":"MS Talamonti","year":"2002","unstructured":"Talamonti MS, Goetz LH, Rao S, Joehl RJ (2002) Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 137:564\u2013570","journal-title":"Arch Surg"},{"key":"3371_CR5","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U","volume":"86","author":"JR Howe","year":"1999","unstructured":"Howe JR, Karnell LH, Menck HR, Scott-Conner C (1999) The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985\u20131995. Caner 86:2693\u20132706","journal-title":"Caner"},{"key":"3371_CR6","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","volume":"27","author":"MJ Overman","year":"2009","unstructured":"Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA (2009) Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 27:2598\u20132603. doi:\n                        10.1200\/JCO.2008.19.7145","journal-title":"J Clin Oncol"},{"key":"3371_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","volume":"23","author":"XJ Xiang","year":"2012","unstructured":"Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, Yan J, Zhao JG, Xiong JP (2012) A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs 23:561\u2013566. doi:\n                        10.1097\/CAD.0b013e328350dd0d","journal-title":"Anticancer Drugs"},{"key":"3371_CR8","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/cncr.25614","volume":"117","author":"A Zaanan","year":"2011","unstructured":"Zaanan A, Gauthier M, Malka D, Locher C, Gornet JM, Thirot-Bidault A, Tougeron D, Ta\u00efeb J, Bonnetain F, Aparicio T (2011) Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicentre AGEO study. Cancer 117:1422\u20131428. doi:\n                        10.1002\/cncr.25614","journal-title":"Cancer"},{"key":"3371_CR9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1634\/theoncologist.2012-0079","volume":"17","author":"T Tsushima","year":"2012","unstructured":"Tsushima T, Taguri M, Honma Y et al (2012) Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist 17:1163\u20131170","journal-title":"Oncologist"},{"key":"3371_CR10","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/annonc\/mdq038","volume":"21","author":"A Zaanan","year":"2010","unstructured":"Zaanan A, Costes L, Gauthier M et al (2010) Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 21:1786\u20131793. doi:\n                        10.1093\/annonc\/mdq038","journal-title":"Ann Oncol"},{"key":"3371_CR11","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705. doi:\n                        10.1200\/JCO.2009.27.4860","journal-title":"J Clin Oncol"},{"key":"3371_CR12","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019. doi:\n                        10.1200\/JCO.2007.14.9930","journal-title":"J Clin Oncol"},{"key":"3371_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, ToGA Trial Investigators et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687\u2013697. doi:\n                        10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"key":"3371_CR14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, RAINBOW Study Group et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235. doi:\n                        10.1016\/S1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"key":"3371_CR15","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1038\/bjc.2013.677","volume":"109","author":"T Aparicio","year":"2013","unstructured":"Aparicio T, Svrcek M, Zaanan A et al (2013) Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer 109:3057\u20133061. doi:\n                        10.1038\/bjc.2013.677","journal-title":"Br J Cancer"},{"key":"3371_CR16","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cncr.30445","volume":"123","author":"P Gulhati","year":"2017","unstructured":"Gulhati P, Raghav K, Shroff RT et al (2017) Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: a single-center, open-label, phase 2 study. Cancer 123:1011\u20131017","journal-title":"Cancer"},{"key":"3371_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.04.013","author":"D Aydin","year":"2016","unstructured":"Aydin D, Sendur MA, Kefeli U et al (2016) Evaluation of bevacizumab in advanced small bowel adenocarcinoma. Clin Corolectal Cancer. doi:\n                        10.1016\/j.clcc.2016.04.013","journal-title":"Clin Corolectal Cancer"},{"key":"3371_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/sj.bjc.6605898","volume":"103","author":"D Santini","year":"2010","unstructured":"Santini D, Fratto ME, Spoto C, Russo A, Galluzzo S, Zoccoli A, Vincenzi B, Tonini G (2010) Cetuximab in small bowel adenocarcinoma: a new friend? Br J Cancer 103:1305. doi:\n                        10.1038\/sj.bjc.6605898","journal-title":"Br J Cancer"},{"key":"3371_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. doi:\n                        10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3371_CR20","unstructured":"National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. \n                        http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                        \n                    . Accessed 10 Feb 2017"},{"key":"3371_CR21","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012","journal-title":"J Clin Oncol"},{"key":"3371_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.amjsurg.2009.05.037","volume":"199","author":"TR Halfdanarson","year":"2010","unstructured":"Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF (2010) A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 199:797\u2013803. doi:\n                        10.1016\/j.amjsurg.2009.05.037","journal-title":"Am J Surg"},{"key":"3371_CR23","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1245\/s10434-010-1109-x","volume":"17","author":"MB Nicholl","year":"2010","unstructured":"Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G (2010) Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol 17:2728\u20132732. doi:\n                        10.1245\/s10434-010-1109-x","journal-title":"Ann Surg Oncol"},{"key":"3371_CR24","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1002\/cncr.25324","volume":"116","author":"MJ Overman","year":"2010","unstructured":"Overman MJ, Hu CY, Wolff RA, Chang GJ (2010) Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 116:5374\u20135382. doi:\n                        10.1002\/cncr.25324","journal-title":"Cancer"},{"key":"3371_CR25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00439-003-1027-0","volume":"114","author":"IJ Kim","year":"2003","unstructured":"Kim IJ, Park JH, Kang HC, Shin Y, Park HW, Park HR, Ku JL, Lim SB, Park JG (2003) Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 114:118\u2013120","journal-title":"Hum Genet"},{"key":"3371_CR26","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/annonc\/mdq591","volume":"22","author":"M Moehler","year":"2011","unstructured":"Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR (2011) Cetuximab with irinotecan folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 22:1358\u20131366. doi:\n                        10.1093\/annonc\/mdq591","journal-title":"Ann Oncol"},{"key":"3371_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/sj.bjc.6605521","volume":"102","author":"F Lordick","year":"2010","unstructured":"Lordick F, Luber B, Lorenzen S et al (2010) Cetuximab plus oxaliplatin\/leucovorin\/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102:500\u2013505. doi:\n                        10.1038\/sj.bjc.6605521","journal-title":"Br J Cancer"},{"key":"3371_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(08)70232-8","volume":"9","author":"JJ Koornstra","year":"2008","unstructured":"Koornstra JJ, Kleibeuker JH, Vasen HF (2008) Small-bowel cancer in Lynch syndrome: is it time for surveillance? Lancet Oncol 9:901\u2013905. doi:\n                        10.1016\/S1470-2045(08)70232-8","journal-title":"Lancet Oncol"},{"key":"3371_CR29","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ijc.23508","volume":"123","author":"P Watson","year":"2008","unstructured":"Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, J\u00e4rvinen HJ, Myrh\u00f8j T, Sunde L, Wijnen JT, Lynch HT (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444\u2013449. doi:\n                        10.1002\/ijc.23508","journal-title":"Int J Cancer"},{"key":"3371_CR30","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0016-5085(99)70510-X","volume":"116","author":"HF Vasen","year":"1999","unstructured":"Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116:1453\u20131456","journal-title":"Gastroenterology"},{"key":"3371_CR31","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968\u20133976. doi:\n                        10.1200\/JCO.2011.36.2236","journal-title":"J Clin Oncol"},{"key":"3371_CR32","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C et al (2016) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17:738\u2013746. doi:\n                        10.1016\/S1470-2045(16)00150-9","journal-title":"Lancet Oncol"},{"key":"3371_CR33","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.3978\/j.issn.2078-6891.2013.038","volume":"5","author":"G Nagaraj","year":"2014","unstructured":"Nagaraj G, Zarbalian Y, Flora K, Tan BR Jr (2014) Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6. J Gastrointest Oncol 5:E1\u2013E6. doi:\n                        10.3978\/j.issn.2078-6891.2013.038","journal-title":"J Gastrointest Oncol"},{"key":"3371_CR34","first-page":"2792","volume":"37","author":"K Okubo","year":"2010","unstructured":"Okubo K, Yoshioka S, Asukai K et al (2010) A case report of primary adenocarcinoma of small intestine. Gan To Kagaku Ryoho 37:2792\u20132794","journal-title":"Gan To Kagaku Ryoho"},{"key":"3371_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/sj.bjc.6605449","volume":"102","author":"MJ Overman","year":"2010","unstructured":"Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H (2010) Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102:144\u2013150. doi:\n                        10.1038\/sj.bjc.6605449","journal-title":"Br J Cancer"},{"key":"3371_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559\u2013568. doi:\n                        10.1016\/S1470-2045(09)70112-3","journal-title":"Lancet Oncol"},{"key":"3371_CR37","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","volume":"14","author":"M Kozloff","year":"2009","unstructured":"Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A (2009) Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14:862\u2013870. doi:\n                        10.1634\/theoncologist.2009-0071","journal-title":"Oncologist"},{"key":"3371_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76\u201382. doi:\n                        10.1200\/JCO.2007.12.1939","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3371-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T06:29:09Z","timestamp":1501136949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3371-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3371"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3371-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]}}}